Table 1.
Demographic data of the patients included in the study
| Group A: PreserFlo + Phaco/PCL | Group B: PreserFlo | P | |
|---|---|---|---|
| Gender (females/males) | 12/3 | 10/5 | |
| Age | 62±9.02 | 73.53±10.52 | 0.002 |
| Eye (RE/LE) | 6/9 | 4/11 | |
| Baseline MD (dB) | −12.34±10.69 | −13.68±8.49 | 0.36 |
| Baseline IOP (mmHg) | 23.47±8.99 | 23.4±8.68 | 0.49 |
| Baseline antiglaucoma agents | 3.33±1.02 | 2.4±1.45 | 0.06 |
| Baseline BCVA (Snellen) | 0.7±0.23 | 0.6±0.24 | 0.13 |
| Baseline CD | 0.89±0.12 | 0.89±0.14 | 0.49 |
| Baseline RNFL thickness | 60.14±15.35 | 71±15.87 | 0.04 |
| Operation | |||
| PreserFlo + MMC | 8 | 12 | |
| PreserFlo + MMC + Ologen | 7 | 3 | |
| Total | 15 | 15 | |
| Diagnose | |||
| POAG | 14 | 12 | |
| Pigmentary glaucoma | 1 | 1 | |
| Pseudoexfoliative glaucoma | 0 | 2 | |
| Total | 15 | 15 | |
| Previous surgeries | |||
| Phaco/PCL | 0 | 0 | |
| Canaloplasty | 5 | 3 | |
| mTS-CPC | 3 | 3 | |
| Trabeculectomy | 3 | 0 | |
| Iridectomy | 2 | 0 |
Paired sample t-test was used for the calculation of the P values. BCVA: Best-corrected visual acuity, CD: Cup-disc-ratio, IOP: Intraocular pressure, MD: Mean deviation, mTS-CPC: MicroPulse® transscleral cyclophotocoagulation, Phaco: Phacoemulsification, PCL: Posterior capsular lens, RNFL: Retinal nerve fiber layer, MMC: Mitomycin C, POAG: Primary open-angle glaucoma